33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4873)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - A randomized, double-blind, placebo-controlled, phase 3 study
    Meeting Abstract

    Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S. E.; Hyung, W. J.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
    Meeting Abstract

    Stein, A.; Lordick, F.; Janjigian, Y. Y.; Oh, D. Y.; Lee, K. W.; Steeghs, N.; Chao, Y.; DI Bartolomeo, M.; Garcia, M. D.; Mohammad, N. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC)
    Meeting Abstract

    Müller, V.; Turner, N.; Jhaveri, K.; Bardia, A.; Niikura, N.; Diéras, V.; Barrios, C.; Im, S. A.; Bellet, M.; Chang, C. W.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Meeting Abstract

    Kolberg, H. C.; André, F.; Hamilton, E.; Loi, S.; Schmid, P.; Anders, C.; Yu, T.; Boston, S.; D'cruz, C.; Herbolsheimer, P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Tractable patient-derived models for preclinical therapeutic studies of CNS metastases
    Meeting Abstract

    Vojnic, M.; Odintsov, I.; Offin, M. D.; Lui, A. J. W.; Khodos, I.; Chang, Q.; Mattar, M. S.; De Stanchina, E.; Ladanyi, M.; Somwar, R.
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and nonsmall cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)]
    Meeting Abstract

    Ullrich, R.; Wermke, M.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'Angelo, S. P.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Improving acute stroke response at a comprehensive cancer center: A multidisciplinary hospital-based quality improvement project
    Meeting Abstract

    Quashie, W.; Avila, E.; Barzola, M.; Buchholz, T.; Majeed, J.; Santa Maria, N.; Schaff, L.
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1, safety lead-in and randomized, open-label, perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH-1 mutant astrocytomas: Trial in progress
    Meeting Abstract

    Wen, P.; Mellinghoff, I.; Clarke, J.; Puduvalli, V.; de Groot, J.; Liu, H.; Tron, A.; Chisamore, M.; Steelman, L.; Hassan, I.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Permanent carrier-embedded Cesium-131 brachytherapy for the salvage treatment of previously irradiated, recurrent brain metastases
    Meeting Abstract

    Imber, B.; Beal, K.; Reiner, A.; Giantini-Larsen, A.; Yang, J.; Aramburu-Nunez, D.; Cohen, G.; Brennan, C.; Tabar, V.; Young, R.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Utility of the Seizure Control Composite Index (RANO-SCCI) in evaluating seizures in CNS tumor patients
    Meeting Abstract

    Miller, H.; Christ, A.; Grajkowska, E.; Acquaye, A.; Adegbesan, K.; Boris, L.; Burton, E.; Chambers, C.; Choi, A.; Evans, K.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save